TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants Who Had Brain Metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Amount of blood at surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Condition of haemostasis after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maintenance of cessation of bleed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Participants With an IUD Expulsion (Complete) at 6 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in DAS28-ESR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extreme sensory processing patterns
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Analog Scale for Pain (VAS Pain) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional somatic disorder at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional somatic disorder at 5-year follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic fatigue at 5-year follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with ovulation recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: C-peptide measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Amount of Vancomycin and Tobramycin Eluted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of vancomycin removed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maternal blood glucose control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of body fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Velocimetric measurements of temporal arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of time with SpO2 within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Live birth rate per initiated cycle
Endpoint domain: Mortality/survival
Primary endpoint: Patellar cartilage thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: AUCt of CKD-330, D090, CKD-333
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CKD-330, D090, CKD-333
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ferropenic anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Risk of hemoconcentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Patients Passing Their Stone Within 28 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exhaled breath nitric oxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric and esophageal motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lower esophageal sphincter tone changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total patient costs accrued for musculoskeletal care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total patient charges submitted for musculoskeletal care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of Patients P0 at Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of Patients With Negative Surgical Margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prostate-specific Antigen Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to Clinical Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time in range for glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median change from baseline in serum HCV RNA (log10 IU/mL) at day 22
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median change from baseline in serum ALT at day 22
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients with serum HCV RNA declining at least a 1 log10 from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole gut transit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of opioid pills reported being taken by the patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of opioid pills being prescribed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Volume changes of targets and organs at risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of neutrophils adherent to TNFα-stimulated endothelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Discharge status
Endpoint domain: Mortality/survival
Primary endpoint: sensitivity/specificity of the fully-automatic device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients obtaining disease control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: scarring in middle meatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver function tests (LFTs) serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food Acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse events / Serious adverse events (AE/SAE) monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Global Impression Severity & Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Cumulative Irritation Index During Induction Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Sensitization Reactions During Challenge Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Overall efficacy of the community mobilization intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Modified Observer's Assessment Alertness Scale (MOAA/S) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in antiretroviral medication adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of major adverse cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Two Day Nadir Serum Asparaginase Activity Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progesterone variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lack of Lung Doppler signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of Postoperative Hemorrhagic Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Clinic Evaluations of Postoperative Hemorrhagic Complications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of Treatment Interventions for Postoperative Hemorrhagic Complications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of concentration of pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to full weaning from ventilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Episodes of atelectasis
Endpoint domain: Adverse events/effects
Primary endpoint: Episodes of ventilator-acquired pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Response pattern to inhaled short acting B2 agonist
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total mNIHSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quit Attempt
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Efficacy of PICC placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement of Nausea and Vomiting of Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean difference of visual analogue scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of complications after colorectal surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Visual Acuity Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial Irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cutaneous Effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Median Overall Survival Time
Endpoint domain: Mortality/survival
Primary endpoint: eNO measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: total number of amphetamine- and methamphetamine-negative samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abstinence defined as five or more consecutive weeks of amphetamine- and MA-negative samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment program retention
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Change in Visual Acuity From Baseline to Six Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Optical Coherence Tomography Measured Central Subfield Thickness From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of satisfaction with the mouthguard
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severity of osteoarthrosis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rifampicin and Moxifloxacin concentration in plasma and CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in peri implant radiolucency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutamate + Glutamine (Glx) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving SVR 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: infection frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under The Concentration Versus Time Curve (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Tumor Perfusion (Ft)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provocative Dose 2 (PD2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with viral load < 400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Type and frequency of infusion reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Structural and functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrophysiological brain response characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cmax of SKF101468 (Ropinirole) and Its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmin of SKF101468 (Ropinirole) and Its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-24 of SKF101468 (Ropinirole) and Its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of SKF101468 (Ropinirole) and Its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Trough Concentrations of SKF101468 (Ropinirole) and Its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of volatile organic compounds profiles in exhaled air
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenotype and genotype discrepancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of nocturia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough FEV1 (Change From Baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Standardized FEV1AUC0-12 Area Under the FEV1 Curve From 0 to 12 Hours Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak FEV1 (Change From Baseline and Percent Change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of successful radiotherapy sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of interruptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Motor Nerve Conduction Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Distal Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: F Wave Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Length of Motor Nerve Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adalimumab (ADA) trough level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Lacrimal Tear Lake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasma Phe Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pressure Pain Threshold (PPT)-Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to radiographic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of instability recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Daily Frequency of Hot Flashes Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Severity of Hot Flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of atomoxetine compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of Verrucae (Warts)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-τ(ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cτ(ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of breath biomarkers with blood glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of resource limitations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PI difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PVI difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diacylglycerol molecular species accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Unified Parkinson's Disease Rating Scale (UPDRS) parts II and III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in ambulatory nocturnal blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complication by transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of active lower gastrointestinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Wang score after 72 hours of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative symptom domain of psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of piritramide
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: HPV Vaccination Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Presence of MMP-8 in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MAS (Modified Ashworth Scale) grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Standard deviation of repeated StO2 level measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Organ specific outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of testicular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change of blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biodistribution of gallium Ga 68 FAPi-46 and gallium Ga 68-labeled PSMA-11
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with 4-fold or greater rises in RSV neutralizing antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Alive Ventilator-free Days
Endpoint domain: Mortality/survival
Primary endpoint: MSNA increase during CPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of vitiligo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Keratinization index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Glycosylated Hemoglobin Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brain Functional Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Achieving DAS 28 ≤3.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfusion of packed red cells (mL/kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concordance Between Investigational Allergen and Reference Allergen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Auditory Tone Matching Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parents' presence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parent-infant skin-to-skin contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parents' satisfaction to family centered care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of GSK1605786
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessed Pregnancy Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Level of Smoke Inhalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regulatory T Cell FOXP3 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Remission rate of proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants Free From Inappropriate Pacemaker Function Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: severity of seborrheic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety profile of seletracetam
Endpoint domain: Adverse events/effects
Primary endpoint: treatment response classification
Endpoint domain: Mortality/survival
Primary endpoint: Revision for loosening
Endpoint domain: Adverse events/effects
Primary endpoint: platelet/coagulation/fibrinolytic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes